Gilead's NASH drug fails to meet study goals for 2nd time

A late-stage study for Gilead Science's drug to treat fibrosis symptoms associated with nonalcoholic steatohepatitis didn't meet its goal of treating disease symptoms last week.

Three key details:

1. The drug, selonsertib, failed to improve NASH symptoms in the study, which took place two months after a previous study during which the drug failed. NASH is a nonalcoholic fatty liver disease that can cause fatigue, nausea and weight loss.

2. The trial involved patients with compensated cirrhosis, an advanced form of NASH.

3. In a statement, John McHutchison, chief scientific officer and head of research and development for Gilead Sciences, said: "We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast